A team of scientists in the United States has identified a novel biological mechanism that could reshape the treatment landscape for Alzheimer’s disease. The research, conducted at the Indiana University School of Medicine, focuses on an enzyme known as IDOL, which appears to play a significant role in the progression of the condition.
Alzheimer’s disease, one of the leading causes of dementia worldwide, is characterised by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. In recent years, therapeutic advances have included regulatory approval by the U.S. Food and Drug Administration of drugs such as lecanemab and donanemab, both designed to slow disease progression by targeting amyloid deposits. However, researchers continue to explore alternative biological targets that may provide broader or more durable benefits.
The latest findings, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggest that suppressing the IDOL enzyme in brain cells could significantly reduce the formation of amyloid plaques. Notably, the most pronounced effects were observed when the enzyme was removed from neurons rather than from microglial cells, which are typically associated with immune defence in the brain.
Further analysis revealed that altering IDOL activity in neurons also influenced levels of apolipoprotein E (APOE), a protein closely linked to Alzheimer’s risk. Certain variants of APOE, particularly APOE4, are well established in scientific literature as major genetic contributors to late-onset Alzheimer’s disease. The modulation of this protein suggests that IDOL may affect not only plaque accumulation but also lipid metabolism within the brain, an area increasingly recognised as critical in neurodegenerative disorders.
In addition to reducing pathological markers, the study indicated improvements in cellular mechanisms associated with neuronal communication. Researchers observed increased activity of receptors involved in regulating both amyloid and APOE pathways, which may support synaptic integrity and cognitive resilience. These findings align with prior peer-reviewed studies suggesting that enhancing neuronal resistance to damage could be as important as reducing toxic protein accumulation.
From a clinical perspective, this dual effect is particularly relevant. Alzheimer’s disease is often diagnosed after significant neurological damage has already occurred. Strategies that both limit further degeneration and strengthen the brain’s ability to cope with existing pathology may therefore offer greater therapeutic value.
The research team is now advancing towards drug development, aiming to design compounds capable of selectively inhibiting the IDOL enzyme. As enzymes present defined molecular structures, they are considered suitable targets for precision therapies. Future investigations will focus on safety profiles, efficacy in preclinical models, and the potential impact on other hallmarks of Alzheimer’s disease, including tau-related neurodegeneration.
Although still in the experimental phase, this discovery represents a meaningful step in the ongoing effort to better understand and treat Alzheimer’s disease. It reinforces the importance of diversified research approaches in addressing complex neurological conditions, particularly as global populations continue to age and the burden of dementia rises.